Altimmune (NASDAQ:ALT) Trading 7.2% Higher – What’s Next?

30 Jan 2026, 18:22 by Mitch Edgeman · The Markets Daily

Shares of Altimmune, Inc. (NASDAQ:ALT – Get Free Report) rose 7.2% during trading on Friday . The stock traded as high as $5.48 and last traded at $5.4650. Approximately 2,268,356 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 6,454,089 shares. The stock had previously closed at $5.10.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALT. Barclays initiated coverage on Altimmune in a research report on Tuesday. They set an “overweight” rating and a $20.00 target price for the company. Citizens Jmp cut their price target on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.17.

Get Our Latest Research Report on ALT

Altimmune Price Performance

The firm has a market cap of $575.44 million, a P/E ratio of -5.14 and a beta of 0.04. The firm’s fifty day simple moving average is $4.65 and its 200 day simple moving average is $4.15. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18.

Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. As a group, analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jerome Benedict Durso bought 12,500 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the purchase, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,625. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John Gill acquired 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the purchase, the director owned 12,500 shares of the company’s stock, valued at $51,250. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 30,527 shares of company stock worth $125,278. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Altimmune

A number of large investors have recently bought and sold shares of ALT. Vanguard Group Inc. raised its position in shares of Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after acquiring an additional 1,206,514 shares in the last quarter. Two Sigma Investments LP grew its stake in Altimmune by 356.6% in the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after purchasing an additional 1,559,562 shares during the last quarter. Geode Capital Management LLC grew its stake in Altimmune by 13.4% in the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after purchasing an additional 228,995 shares during the last quarter. Federated Hermes Inc. raised its holdings in Altimmune by 387.7% in the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock worth $3,543,000 after purchasing an additional 727,731 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Altimmune by 155.2% during the second quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock valued at $2,771,000 after buying an additional 435,467 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

(Get Free Report)

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.